Healthcare & Clinical
NAFLD Fibrosis Score: historical equation and limitations
Practice the historical NAFLD Fibrosis Score equation using fictional inputs, with its units, study context and modern guidance.
The historical score and its intended population
The 2007 NAFLD Fibrosis Score (NFS) was developed to help assess advanced fibrosis in people with biopsy-confirmed nonalcoholic fatty liver disease. The original study used 480 participants for model development and 253 for validation. MASLD is newer terminology with diagnostic criteria that are not identical to the older NAFLD definition.
The equation uses age in completed years, BMI in kg/m², a clinician-assessed impaired fasting glucose or diabetes indicator (0 or 1), AST and ALT in the same units, platelet count in 10⁹/L and albumin in g/dL. AST/ALT is a ratio; do not interchange AST and ALT or use albumin in g/L without conversion. This fictional exercise demonstrates the equation, not diagnosis.
| Input | Example unit or coding |
|---|---|
| Age | Completed years (adult example) |
| BMI | kg/m² |
| Impaired fasting glucose or diabetes | 0 = absent, 1 = present, as assessed |
| AST and ALT | Same units, for example U/L |
| Platelets | 10⁹/L |
| Albumin | g/dL |
Calculate with complete numeric inputs
The equation below requires seven numeric inputs, an adult whole-number age, positive measurements and a binary glucose/diabetes indicator. For the fictional example 58 years, BMI 33.5, indicator 1, AST 68, ALT 52, platelets 165 and albumin 3.8, the rounded result is 1.392. The input checks cannot validate a measurement, a diagnosis or whether the model is appropriate.
=IF(COUNT(B2:B8)<>7,"Complete all seven numeric inputs",IF(OR(B2<18,B2<>INT(B2),B3<=0,AND(B4<>0,B4<>1),B5<=0,B6<=0,B7<=0,B8<=0),"Invalid inputs",ROUND(-1.675+0.037*B2+0.094*B3+1.13*B4+0.99*(B5/B6)-0.013*B7-0.66*B8,3)))Interpretation depends on the population and setting
The original study reported thresholds of −1.455 and 0.676 and used a middle range for indeterminate results. Its predictive values came from the study cohorts and are not guaranteed probabilities for an individual or a different population. A score by itself does not establish a fibrosis stage, exclude all advanced fibrosis, or prescribe a specific test or treatment.
The 2024 EASL–EASD–EASO guidance describes a multistep MASLD assessment using a blood-based score such as FIB-4 and, when indicated, elastography. It also notes reduced performance of NFS in people younger than 35. The appropriate pathway and follow-up depend on the full clinical context.
Try the example
Use the original values or change them to test your understanding.